Novel Drug Discovery and Development
Lupin’s Novel Drug Discovery and Development (NDDD) team focuses on developing a portfolio of highly differentiated and innovative chemical entities for therapeutic areas such as Oncology, Immunology and Metabolic Disorders.
Our current clinical programmes include a successfully completed clinical Endocrine study in Europe. Another study has been initiated on chronic kidney patients in India, including patients on and not on dialysis.
A clinical study in Oncology, comprising terminally ill patients suffering from melanoma, lung and colon cancers, has been successfully completed in Europe. A trial has been underway in India to treat a refractory type of lung cancer which has RAS mutations, and for which no treatment exists worldwide.
Infographic: NDDD focuses on
• Metabolic Disorders
We continue to bolster our capabilities in novel areas of research and inked a licensing and development partnership with Boehringer Ingelheim in FY20 to advance Lupin’s MEK inhibitor programme to treat difficult-to-treat cancers. This partnership will help advance our clinical stage MEK inhibitor LNP3794 for the treatment of patients with gastrointestinal and lung cancers harbouring a broad range of oncogenic KRAS mutations.
An earlier collaboration with AbbVie in 2019 led to the licensing of Lupin’s MALTI (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) Inhibitor Programme.